Health Net, Inc. Provides Coverage for Biodesix’ VeriStrat Test
HealthNet now covers Biodesix' VeriStrat test
254 Results
HealthNet now covers Biodesix' VeriStrat test
Biodesix' VeriStrat test is covered by Cigna
Biodesix raises follow-on series E financing
Biodesix' VeriStrat test has won approval from CareFirst BlueCross BlueShield
Biodesix recently added Biognosys' Proteomics to their capabiltites.
Biodesix named to Inc. 500|5000 Fastest-Growing Private Companies list
Biodesix, Inc and Inivata announced a partnership today to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for lung cancer.
The paper’s authors conclude that using VeriStrat improves overall survival and decreases medical costs in the US payer system.
VeriStrat and Epidermal Growth Factor Receptor Mutation Status Study results presented at 16th World Conference on Lung Cancer
Biodesix data on proteomic and genomic blood-based assays presented at EORTC
Biodesix announced that the VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation.
In addition to the $15 million of series shares in 2013 and 2014, Biodesix brought in another $12 million, for total proceeds of $27 million from the sale.
Investigational blood test identifies patients with melanoma who are more likely to have improved survival on Nivolumab therapy.